Navigation Links
Successful stem cell therapy for treatment of eye disease
Date:12/10/2009

Newcastle, United Kingdom, December, 2009 Newly published research, by investigators, at the North East England Stem Cell Institute (NESCI) in the journal Stem Cells reported the first successful treatment of eight patients with "Limbal Stem Cell Deficiency" (LSCD) using the patients' own stem cells without the need of suppressing their immunity.

LSCD is a painful, blinding disease that requires long-term, costly treatment with frequent clinic visits and intensive hospital admissions. The vision loss due to LSCD makes this disease not only costly, but often requires social support due to the enormous impact on patient's quality of life. This is further magnified by the fact that LSCD mostly affects young patients.

Dr Francisco Figueiredo, a member of the NESCI team, said, "Corneal cloudiness has been estimated to cause blindness in 8 million people (10% of total blindness) worldwide each year. A large number of ocular surface diseases, both acquired and congenital, share features of partial or complete LSCD. "

Chemical burns to the eye are the most common cause of LSCD.

Professor Lako said: "This study demonstrates that transplantation of cultured corneal stem cells without the use of animal cells or products is a safe and effective method of reconstructing the corneal surface and restoring useful sight in patients with unilateral LSCD.

"This research shows promise to help hundreds of people regain their sight. These exciting results offer a new treatment and hope for people with LSCD."

Professor Michael Whitaker FMedSci, Co-Director of NESCI, which is a collaboration between Durham and Newcastle Universities, Newcastle NHS Foundation Trust and other partners, said: "Stem cells from bone marrow have been used successfully for many years to treat cancer and immune disease, but this is the first successful stem cell therapy using stem cells from the eye without animal products to treat disease,
'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related biology news :

1. Pathological gambling may be successfully treated with medications for substance addiction
2. MSU researcher: Obesity significantly cuts odds of successful pregnancy
3. Rare genetic disease successfully reversed using stem cell transplantation
4. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
5. UOG scientists successfully compete for research grants
6. McGill/JGH researchers successfully reverse multiple sclerosis in animals
7. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
8. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
9. Salk researchers successfully reprogram keratinocytes attached to a single hair
10. Gap junction protein vital to successful pregnancy, researchers find
11. Successful series of measurements in Arctic sea ice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... As open enrollment season approaches, U.S. employees will ... 2015 benefits. According to Aon Hewitt , the ... Aon plc (NYSE: AON ), employees ... in managing their health care decisions. This increased responsibility ... understand how they can make the most of the ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... to a morphine regimen can result in better pain ... reduce the dosage of the opioid needed to be ... Indiana University. , The result could bring significant relief ... often felt in the arms and legs and associated ... unmet need for better treatments for neuropathic pain," said ...
Breaking Biology News(10 mins):Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7Scientists discover RNA modifications in some unexpected places 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... the United States are 32 times more likely to ... antibiotic, gentamicin, than others outside the poultry industry, according ... Johns Hopkins Bloomberg School of Public Health. While drug-resistant ... industrial broiler chicken environment, this is the first U.S. ...
... possum and a giant rat were recorded by scientists as ... and virtually unknown Lost World in the pristine wilderness of ... Indonesia Institute of Science (LIPI) scientists were accompanied by the ... its wildlife on an expedition to the Fojas in June ...
... the Neural Basis of Cognition (CNBC), a joint project ... have for the first time described a mechanism called ... the fly allowing stimuli to be more keenly sensed. ... the January 2008 issue of Nature Neuroscience, and available ...
Cached Biology News:Poultry workers at increased risk of carrying antibiotic-resistant E. coli 2Indonesia's 'Lost World' reveals more surprises 2Neuronal circuits able to rewire on the fly to sharpen senses 2
(Date:9/16/2014)... , September 16, 2014 BCC ... MARKET FOR STEM CELLS , the global market for ... billion by 2018, with a five-year compound annual growth ... witnessed in the Americas with growth projections of $2.2 ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
(Date:9/15/2014)... made of carbon nanotubes is neat, but Rice University scientists ... nanotubes in new fibers created at Rice line up like ... chemist Angel Mart and his colleagues. , The tricky bit, ... in the journal ACS Nano , is keeping the ... fiber. , Left to their own devices, carbon nanotubes form ...
(Date:9/15/2014)... 15, 2014 Research and Markets has ... by Product, by Services, by Technology, by Application - Global ... Whole Exome Sequencing (WES) is next-generation technology used for ... exon. The exome, which is the total of all exons ... and is actually converted into proteins after translation. It is ...
Breaking Biology Technology:Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3
... 4 Immtech Pharmaceuticals,Inc. (AMEX: IMM ) ... exclusive,license to BioAlliance Pharma SA (Euronext Paris - ... maleate (pafuramidine), in,Europe for the treatment of pneumocystis ... of Human African trypanosomiasis, also known as,African sleeping ...
... Israel, December 4 Healthcare,Technologies Ltd. (NASDAQ: ... its unaffiliated and voting shareholders (approximately 90%),voted in ... the meeting, the shareholders were asked to approve ... Inc, Mac,Bioventures Inc. and Gamida for Life B.V. ...
... Biotest Pharmaceuticals,Corporation, a leading developer of ... management team as part of the formal,completion ... (Nasdaq:,NABI) and the creation of Biotest Pharmaceuticals. ... Corporation Completes Acquisition,of Nabi Biologics Business Unit," ...
Cached Biology Technology:Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction 2Biotest Pharmaceuticals Corporation Announces Management Team 2Biotest Pharmaceuticals Corporation Announces Management Team 3